Yutaka Hanaoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yutaka Hanaoka has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Shigeo Toda
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
10 shared publications - Shuichiro Matoba
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
10 shared publications - Adham Jurdi
Natera, Inc., Austin, TX, USA
7 shared publications - Akiko Chino
Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
7 shared publications - Antony Tin
Natera, Inc. 4 , San Carlos, California
7 shared publications - Eiji Shinozaki
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
7 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- 7 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5188-5197
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117
- 7 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5188-5197
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117
- 1 September 2018
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 22 (9) , 719-724
Laparoscopic intersphincteric resection of rectal cancer with posterior vaginal wall excision without hysterectomy
- 1 September 2018
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 22 (9) , 719-724
Laparoscopic intersphincteric resection of rectal cancer with posterior vaginal wall excision without hysterectomy
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3568
Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer.
3568 Background: The programmed death-1 (PD-1)/PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. PD-L1 was expressed on tumor cells (TCs) or tumor-infiltrating immune cells (ICs) in several malignancies. We previously reported that high PD-L1 expression on TCs and ICs were associated with poor and better prognosis in patients with stage IIIb colorectal cancer, respectively. We reported whether these findings were validated in patients with stage III colorectal cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) blocks specimens were obtained from the patients with stage III colorectal cancer who underwent surgical resection and adjuvant chemotherapy at our institution between January 2009 and July 2012. We excluded patients who received radiotherapy or chemoradiotherapy before surgery. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TCs and ICs. Specimens were scored as IHC low (L) or high (H), when < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Two hundred and thirty-five patients were included in this analysis. Median age was 63 years (range 32-84). One hundred and seventy-four and 61 patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The number of patients with PD-L1 expression on TCs/ICs (H/H, H/L, L/H, and L/L) was 0, 19, 36, and 180, respectively. The median follow-up time of this study was 52.9 months. Patients with high PD-L1 expression on TCs had significantly shorter disease-free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21-4.62; p = 0.012). Meanwhile, patients with high PD-L1 expression on ICs were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16-0.98; p = 0.046). Conclusions: High PD-L1 expression on TCs negatively affect the survival, whereas high PD-L1 expression on ICs is associated with favorable prognosis of patients with stage III colorectal cancer.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3568
Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer.
3568 Background: The programmed death-1 (PD-1)/PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. PD-L1 was expressed on tumor cells (TCs) or tumor-infiltrating immune cells (ICs) in several malignancies. We previously reported that high PD-L1 expression on TCs and ICs were associated with poor and better prognosis in patients with stage IIIb colorectal cancer, respectively. We reported whether these findings were validated in patients with stage III colorectal cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) blocks specimens were obtained from the patients with stage III colorectal cancer who underwent surgical resection and adjuvant chemotherapy at our institution between January 2009 and July 2012. We excluded patients who received radiotherapy or chemoradiotherapy before surgery. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TCs and ICs. Specimens were scored as IHC low (L) or high (H), when < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Two hundred and thirty-five patients were included in this analysis. Median age was 63 years (range 32-84). One hundred and seventy-four and 61 patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The number of patients with PD-L1 expression on TCs/ICs (H/H, H/L, L/H, and L/L) was 0, 19, 36, and 180, respectively. The median follow-up time of this study was 52.9 months. Patients with high PD-L1 expression on TCs had significantly shorter disease-free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21-4.62; p = 0.012). Meanwhile, patients with high PD-L1 expression on ICs were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16-0.98; p = 0.046). Conclusions: High PD-L1 expression on TCs negatively affect the survival, whereas high PD-L1 expression on ICs is associated with favorable prognosis of patients with stage III colorectal cancer.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 611
Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with stage IIIb colorectal cancer.
611 Background: Programmed death 1 (PD-1)/ PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. Some previous studies showed that positive PD-L1 expression on tumor cells (TC) was poor prognostic factor in patients with colorectal cancer; however, recent studies suggest that IC also play important roles to determine the prognosis in cancer patients. The aim of this study is to investigate the association of clinical and pathological features with PD-L1 expression on TC and IC. Methods: We retrospectively reviewed data of consecutive patients with stage IIIb colorectal cancer (Japanese classification of colorectal carcinoma The 8th Edition), who underwent surgery and received adjuvant chemotherapy in our institution between January 2009 and July 2012. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TC and IC. Specimens were scored as IHC low (L) or high (H), if < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Seventy-four patients were included in this analysis. Median age was 61 years (range 32-84). Thirty-one (41.9%) and 43 (58.1%) patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The median follow-up time was 51.3 months (range 4.6-75.9). The number of patients with PD-L1 expression on TC/IC (H/H, H/L, L/H, and L/L) were 0, 12, 11, and 51, respectively. The median disease-free survival (DFS) in patients with high and low PD-L1 expression on TC were 29.9 months and “not reached”, respectively (hazard ratio [HR] 2.02; 95% confidence interval [CI], 0.85-4.30; P = 0.11). The median DFS in patients with high and low PD-L1 expression on IC were “not reached” and 55.1 months, respectively (HR 0.29; 95%CI, 0.05-0.95; P = 0.04). Conclusions: Although high PD-L1 expression on TC is associated with poor prognosis, high PD-L1 expression on IC positively affects the survival in patients with stage IIIb colorectal cancer.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 611
Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with stage IIIb colorectal cancer.
611 Background: Programmed death 1 (PD-1)/ PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. Some previous studies showed that positive PD-L1 expression on tumor cells (TC) was poor prognostic factor in patients with colorectal cancer; however, recent studies suggest that IC also play important roles to determine the prognosis in cancer patients. The aim of this study is to investigate the association of clinical and pathological features with PD-L1 expression on TC and IC. Methods: We retrospectively reviewed data of consecutive patients with stage IIIb colorectal cancer (Japanese classification of colorectal carcinoma The 8th Edition), who underwent surgery and received adjuvant chemotherapy in our institution between January 2009 and July 2012. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TC and IC. Specimens were scored as IHC low (L) or high (H), if < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Seventy-four patients were included in this analysis. Median age was 61 years (range 32-84). Thirty-one (41.9%) and 43 (58.1%) patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The median follow-up time was 51.3 months (range 4.6-75.9). The number of patients with PD-L1 expression on TC/IC (H/H, H/L, L/H, and L/L) were 0, 12, 11, and 51, respectively. The median disease-free survival (DFS) in patients with high and low PD-L1 expression on TC were 29.9 months and “not reached”, respectively (hazard ratio [HR] 2.02; 95% confidence interval [CI], 0.85-4.30; P = 0.11). The median DFS in patients with high and low PD-L1 expression on IC were “not reached” and 55.1 months, respectively (HR 0.29; 95%CI, 0.05-0.95; P = 0.04). Conclusions: Although high PD-L1 expression on TC is associated with poor prognosis, high PD-L1 expression on IC positively affects the survival in patients with stage IIIb colorectal cancer.